SBIR/STTR Research Award
Peptide-mediated apheresis for inflammatory bowel diseases
Award amount
$280,768Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AFFINERGY, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YJQ6K1QMS488
- Solicitation number
- PA13-234
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): Inflammatory Bowel Disease (IBD), comprised primarily of ulcerative colitis (UC) and Crohn's disease (CD), is characterized by a chronic, uncontrolled inflammation of the intestinal mucosa. As many as 1.4 Million peoplein the United States and 2.2 Million people in Europe currently suffer from IBD, with 30,000 new cases reported each year in the US. Unfortunately, there is no cure for IBD, which necessitates a lifetime of care. There are limited treatment options for CDand UC in the United States, and patients typically receive corticosteroids and immunosuppressive drugs to alleviate symptoms. However, given the toxicity and side effects of these drugs, there is an urgent need for new treatment options for patients withUC and CD. Inflammation of the gastrointestinal tract in IBD is mediated by granulocytes and monocytes. An exciting new therapy for IBD is based on selectively removing these cells from peripheral blood using a strategy known as granulocyte/monocyte
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A novel peptide assay for hepcidin clinical monitoring
- A Rapid Point of Care Test for APOL1 Renal Risk Alleles
- Novel clinical assay to rapidly monitor posaconazole levels in plasma
- Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis
- Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services